FILTER
FILTERED INTERVIEW RESULTS
Dr. Rao Vadlamudi
IMMEDIATE PAST PRESIDENT, INDIAN PHARMACEUTICAL ASSOCIATION AND PRESIDENT, COMMONWEALTH PHARMACISTS ASSOCIATION
The IPA has led India’s pharmaceutical industry from its early conception in 1939 to its rise to become ‘The Pharmacy of the World’ today, and in this interview sets out its views for the industry with GBR.
Bimal L. Goculdas
MANAGING DIRECTOR, DHARAMSI MORARJI CHEMICAL COMPANY
Dharamsi Morarji is a one hundred year old company that has coverted itself from a producer of fertilizers to become a chemical company specialized in handling hazardous substances.
Pramod Thota
PRESIDENT, FMC INDIA
Following its recent acquisition of Dupont’s agro business, FMC is well positioned to extend its dominance of India’s crop protection industry.
Sudhir Shenoy
CEO, DOW INDIA – DOW CHEMICAL
Dow Chemical in India speaks to GBR about its operations and the benefits that Sadara will bring.
H. S. Karangle
DIRECTOR GENERAL, INDIAN CHEMICAL COUNCIL
GBR speaks to the Indian Chemical Council about the prospects for the industry.
L Balakrishna
MANAGING DIRECTOR – INDIA, BRENNTAG
Brenntag’s MD for India speaks to GBR about the challenges particular to that market.
M P Aggrawal
CHAIRMAN, SAJJAN INDIA LIMITED
Sajjan is an Indian contract manufacturer with expertise in large-scale production of active ingredients, electronic chemicals, specialty chemicals and intermediates with applications in agrochemicals, pharmaceuticals and dyes.
Naresh Raisinghani
CEO & EXECUTIVE DIRECTOR, BMGI INDIA
BMGI India offers expertise is improving efficiencies in strategy, innovation, problem solving and business transformation.
Akshay Singh
MANAGING DIRECTOR, SGD PHARMA INDIA
Cogent Glass, recently acquired by SGD Pharma, is a manufacturer of Type I moulded and tubular glass vials for the pharmaceutical industry.
Harish Shah
MANAGING DIRECTOR, SIGNET
Signet is India’s largest excipient company with extensive activities extending to Bangladesh and the Middle East.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
